



Qingyun (Jim) Liu, PhD

Professor and Director, IMM-Center for Translational
Cancer Research

Janice Davis Gordon Chair for Bowel Cancer Research

Member of Texas Therapeutics Institute

Univ. of Texas Health Science Center

Dr. Liu's research has primarily been focused on the identification and characterization of function and signaling mechanism of novel receptors and enzymes for the discovery and development of therapeutics in the area of cancer and immunology. His current research is to continue to investigate the roles and mechanism of RSPO/LGR ligand-receptor system in normal and cancer development with the ultimate goal of validating them as potential drug targets and discovering therapeutic leads. They were the first to demonstrate the use of antagonistic RSPO peptibodies for simultaneous targeting of LGR4/5/6 for cancer treatment. In addition, he is the director of a core facility called "A Preclinical Development Core for Large Molecule Therapeutics" at UTHealth-Houston that is funded by the Cancer Prevention and Institute of Texas (CPRIT). The core's capabilities include detailed pharmacokinetics and toxicology studies of protein drug candidates in rats and monkeys with complete blood analysis and tissue histopathology report